Payment overview · 2025
General Payments
$422.05
22 reported records · 12 companies
Healthcare provider profile · identity verified
Derek J Morrison, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · WEST PLAINS, MO · NPI 1477782621
Verified facts
What the public records show
CMS Open Payments records show Derek J Morrison, D.O. received $422.05 in general payments during 2025 across 22 reported records.
Abbott Laboratories accounted for 28.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $119.78 | 28.4% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $83.60 | 19.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $43.85 | 10.4% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $28.47 | 6.8% | 2 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $27.83 | 6.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.65 | 4.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.13 | 4.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.33 | 4.1% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $16.94 | 4.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.24 | 3.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.30 | 3.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.93 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $422.05 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $119.78 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $61.54 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $61.54 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $43.85 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $28.47 | 2 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $28.47 | 2 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $27.83 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.06 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 80 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
80 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 482 | 147 |
| Levothyroxine Sodium | Levothyroxine Sodium | 353 | 86 |
| Lisinopril | Lisinopril | 330 | 87 |
| Omeprazole | Omeprazole | 281 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 274 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 261 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 228 | 56 |
| Prednisone | Prednisone | 220 | 168 |
| Tramadol Hcl | Tramadol Hcl | 210 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 206 | 53 |
| Alprazolam | Alprazolam | 189 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 186 | 51 |
| Gabapentin | Gabapentin | 169 | 37 |
| Meloxicam | Meloxicam | 168 | 54 |
| Metformin Hcl | Metformin Hcl | 144 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 138 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 126 | 60 |
| Losartan Potassium | Losartan Potassium | 125 | 36 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 119 | 102 |
| Potassium Chloride | Potassium Chloride | 118 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 117 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 34 |
| Sertraline Hcl | Sertraline Hcl | 114 | 34 |
| Furosemide | Furosemide | 109 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 100 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 40 |
| Valsartan | Valsartan | 97 | 29 |
| Carvedilol | Carvedilol | 94 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 11 |
| Mounjaro | Tirzepatide | 80 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 79 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 14 |
| Simvastatin | Simvastatin | 78 | 21 |
| Chlorthalidone | Chlorthalidone | 70 | 20 |
| Montelukast Sodium | Montelukast Sodium | 70 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 17 |
| Eliquis | Apixaban | 63 | 16 |
| Lorazepam | Lorazepam | 59 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | 12 |
| Azithromycin | Azithromycin | 57 | 49 |
| Glimepiride | Glimepiride | 57 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | 16 |
| Lovastatin | Lovastatin | 54 | 16 |
| Trazodone Hcl | Trazodone Hcl | 54 | 13 |
| Metformin Hcl Er | Metformin Hcl | 51 | 13 |
| Pregabalin | Pregabalin | 49 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 14 |
| Finasteride | Finasteride | 47 | 15 |
| Trulicity | Dulaglutide | 46 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | 11 |
| Cephalexin | Cephalexin | 45 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 11 |
| Farxiga | Dapagliflozin Propanediol | 42 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 42 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 40 | 12 |
| Ozempic | Semaglutide | 39 | suppressed |
| Clonidine | Clonidine | 38 | suppressed |
| Allopurinol | Allopurinol | 36 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Celecoxib | Celecoxib | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 34 |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 15 |
| Glipizide | Glipizide | 31 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 25 |
| Glipizide Er | Glipizide | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 22 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 12 |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 19 |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Invokana | Canagliflozin | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 17 |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 12 |
| Amoxicillin | Amoxicillin | 19 | 18 |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 18 | 18 |
| Famotidine | Famotidine | 18 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Fluconazole | Fluconazole | 17 | 14 |
| Indapamide | Indapamide | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 11 |
| Diazepam | Diazepam | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | 11 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $422.05 · 22 records | Abbott Laboratories | AIRSUPRA, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ENFLONSIA, FREESTYLE LIBRE, GARDASIL 9, INGREZZA, LEQVIO, MONOFERRIC, MOUNJARO, Ozempic, REXULTI, Rybelsus, VAXNEUVANCE, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error